Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Claudia Kamfenkel"'
Autor:
Pascale Lejeune, Véronique Cruciani, Axel Berg-Larsen, Andreas Schlicker, Anne Mobergslien, Lisa Bartnitzky, Sandra Berndt, Sabine Zitzmann-Kolbe, Claudia Kamfenkel, Stefan Stargard, Stefanie Hammer, Jennifer S Jørgensen, Malene Jackerott, Carsten H Nielsen, Christoph A Schatz, Hartwig Hennekes, Jenny Karlsson, Alan S Cuthbertson, Dominik Mumberg, Urs B Hagemann
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/05e7344e8ce54a129a43af0ebbd6ec6f
Autor:
Véronique Cruciani, Dominik Mumberg, Axel Berg-Larsen, Carsten H. Nielsen, Andreas Schlicker, Sandra Berndt, Anne Mobergslien, Sabine Zitzmann-Kolbe, Stefan Stargard, Jenny Karlsson, Christoph A. Schatz, Claudia Kamfenkel, Pascale Lejeune, Alan Cuthbertson, Malene Jackerott, Lisa Bartnitzky, Urs B. Hagemann, Hartwig Hennekes, Jennifer S Jørgensen, Stefanie Hammer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundTargeted thorium-227 conjugates (TTCs) are an emerging class of targeted alpha therapies (TATs). Their unique mode of action (MoA) is the induction of difficult-to-repair clustered DNA double-strand breaks. However, thus far, their effects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbf67482a985edcbbfa78279fb48e167
https://jitc.bmj.com/content/9/10/e002387.full
https://jitc.bmj.com/content/9/10/e002387.full
Autor:
Hartwig Hennekes, Carsten Krabbe Nielsen, Urs B. Hagemann, Dominik Mumberg, Jesper Fonslet, Alan Cuthbertson, Claudia Kamfenkel, Dieter Zopf, Christine Ellingsen
Publikováno v:
Cancer Research. 80:5355-5355
Mesothelin-targeted thorium-227 conjugate (MSLN-TTC) is a targeted alpha therapeutic consisting of a MSLN-targeting antibody anetumab covalently attached to a 3,2-HOPO chelator complexed with the alpha emitter thorium-227. It has potent in vivo activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75ca29b3d1d97098711618213a6b8296
https://doi.org/10.1158/1538-7445.am2020-5355
https://doi.org/10.1158/1538-7445.am2020-5355
Autor:
Kathleen Stadelmann, Jenny Karlsson, Christoph A. Schatz, Dominik Mumberg, Urs B. Hagemann, Claudia Kamfenkel, Hartwig Hennekes, Pascale Lejeune, Alan Cuthbertson, Véronique Cruciani, Sandra Berndt, Lisa Bartnitzky, Manuela Steinbach, Stefan Stargard, Roger M. Bjerke, Manuela Brand
Publikováno v:
Cancer Research. 80:2257-2257
Targeted thorium-227 conjugates (TTCs) represent a new class of targeted alpha therapy (TAT). TTCs consist of an antigen targeting moiety, which is covalently attached to a 3,2-HOPO chelator, enabling specific complexation and delivery of the alpha p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2594be365189afc9b4939250e0a6a94
https://doi.org/10.1158/1538-7445.am2020-2257
https://doi.org/10.1158/1538-7445.am2020-2257